Hemastatx is committed to bringing scientific innovation to patients with severe and underserved bleeding disorders, aiming to become a leader in hematology. Founded in 2025 as a spin-off from KU Leuven, Hemastatx builds on over a decade of pioneering research in hemostasis at the Laboratory for Thrombosis Research, led by Prof. dr. Karen Vanhoorelbeke.
Our first lead program, HMX-001, is a proprietary monoclonal antibody designed to stop bleeding in patients with von Willebrand factor (VWF)-related disorders by targeting the underlying biological mechanism. The program is supported by a robust preclinical data package and broad patent protection.
With headquarters in Switzerland and an R&D hub in Belgium, Hemastatx is strategically positioned within two of Europe’s leading biotech ecosystems.
Company Details
- Employees
- 2
- Founded
- 2025
- Address
- Hegenheimermattweg 167a, Allschwil,basel-Country 4123,switzerland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.hemastatx.com
- HQ
- Allschwil, Basel-Country
Hemastatx Questions
Hemastatx's website is http://www.hemastatx.com
Hemastatx's LinkedIn profile is https://ch.linkedin.com/company/hemastatx
Hemastatx has
2 employees.
View email and phone details for 2
employees at Hemastatx.
Hemastatx's industry is
Biotechnology Research
Hemastatx's top competitors are
Agricells,
Oncorna,
Endo Tools Therapeutics,
Immunofusion,
Adipopharma Sas,
Pharmabs,
Mestastop® Solutions,
Hypnovr,
Signatur Biosciences,
Stellaris Therapeutics.
Hemastatx's categories are Biotechnology Research
Hemastatx's founding year is 2025
